Cipla has over 8 decades of caring for life!
1935 - 1960
Esteemed dignitaries visit CIPLA - Sardar Vallabhbhai Patel, Sushila Nayyar, Shanti Swarup Bhatnagar, Ramaswamy Mudaliar, Amrit Kaur, Gulzarilal Nanda, Morarji Desai, Sir C.V. Raman, Crown Prince Fazl of Saudi Arabia, Rafi Ahmed Kidwai, Mohd. Asaf Ali and Maulana Azad
CIPLA celebrates India attaining Independence with flag hoisting ceremony at Mumbai Central Headquarters
CIPLA's advertisement features in the 1948 edition of the MARG journal
CIPLA exhibits at the All India Medical Conference
CIPLA cricket team wins the E-Merck shield
CIPLA's turnover crosses the 1 crore mark.
Installation of an ORG 2001 computer at Mumbai Central Headquarters to ease the process of financial accounts and pay rolls, saving 20 days labour of seven persons.
Inauguration of Patalganga manufacturing plant
Cipla's turnover crosses Rs. 100 crores
Cipla shifts to professional management and announces its new Management Council
Cipla Health Ltd. is established with a vision of becoming the most preferred consumer healthcare company in India
At the 21st International AIDS Conference in Durban, Cipla organises the 'Durban to Durban Forum' - a unique session wherein Dr. Y.K. Hamied delivered a speech marking Cipla's 16-year journey in fighting HIV/AIDS
Cipla launches Synchrobreathe, a state of the - art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
Cipla Palliative Care and Training Centre (CPC) marks its 20th anniversary, with a special program organised by the Cipla Patalganga team
Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™
Cipla completes 85 years on 17th August 2020.
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI).
In continuance of its efforts to advance quality education and promote industry-academia collaboration, Cipla Foundation, funds the set-up of a world class chemistry research laboratory at the Indian Institute of Science Education and Research (IISER) Pune.
Cipla receives Great Place To Work Certification once again.
Cipla receives final approval for generic version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation)
Cipla Foundation supports the set up of Maharashtra's only dedicated pediatric isolation ward for COVID-19
Cipla - Breathe Free Lanka Pvt Ltd. receives Great Place To Work certification. Cipla is one of the top 3 pharma companies in Sri Lanka
Cipla Foundation reaches out to local communities affected by Cyclone Amphan in West Bengal, India by providing essential hygeine and food supplies to those in need.
In June 2020, Cipla Foundation South Africa together with Miltons Matsemela hosted a virtual Youth Day Run to raise funds for frontline COVID healthcare workers.
Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India
Cipla launches remdesivir under its brand name CIPREMI. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.
Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs - Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin)
Cipla is granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in India under the brand name Ciplenza. Favipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.